New Delhi: The Supreme Court last week refused to grant interim relief to Swiss multinational drugmaker Roche, which alleged that Hyderabad-based Natco Pharma was infringing its patent for Evrysdi, with its own, generic formulation Risdiplam.

Both Evrysdi and Risdiplam are used to treat spinal muscular atrophy (SMA).

SMA is a rare genetic disorder that causes progressive muscle weakness and wasting due to the loss of motor neurons—the nerve cells controlling voluntary movement. Show Full Article

Roche’s Evrysdi is currently the only non-invasive, disease-modifying treatment for SMA. It is approved in over 100 countries, with the US Food and Drug Administration (US FDA) recognising it as the “first and only oral treatment” for the condition.

Roche approached the Supreme Court with a sp

See Full Page